Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
OneTwenty
OneTwenty is an early-stage health tech start-up that develops multiple machine learning based solutions for people with diabetes as well as medtech companies for sensor optimization, biomarker…
OneTwenty
OneTwenty is an early-stage health tech start-up that develops multiple machine learning based solutions for people with diabetes as well as medtech companies for sensor optimization, biomarker…
TL;DR
Headquarters: Zurich, Switzerland
Product: bioX — ML-driven predictive glycemic control and digital-twin technology
Regulatory status: Investigational (not yet cleared by MDR or FDA)
Founders: Michael Rottmann (CEO) and Dr. med. Julian M. Stiels (CTO)
Recent financing: First disclosed round led by Dieter von Holtzbrinck Ventures (Jan 2024)
Company Overview
Problem Domain
Diabetes management and glycemic control; sensor optimization and biomarker prediction for medtech.
Founded
2022
Industry
Digital health / Medtech
Funding Track Record
First disclosed financing round; amount not disclosed in available summaries.
Investor Signal
“Includes investors such as Dieter von Holtzbrinck Ventures, Tiny Supercomputer Investment Company (Tiny VC) and individual investor Tim Juergens; Crunchbase lists four investors including Tiny VC and 1921.”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week